• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

New treatment option available for men suffering from benign prostatic hyperplasia

Bioengineer by Bioengineer
July 9, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: UC San Diego Health

Physicians at UC San Diego Health are now offering prostate artery embolization (PAE) as a new treatment option for men with benign prostatic hyperplasia (BPH), or an enlarged prostate. The minimally invasive procedure is an alternative to surgery, with no hospital stay, little operative pain and lower cost.

"PAE has been available in Europe as a treatment option for an enlarged prostate for several years," said Andrew Picel, MD, interventional radiologist at UC San Diego Health. "With the recent FDA approval of this procedure, we are happy to offer this as an alternative to surgery for patients who are good candidates."

Using X-ray guidance, interventional radiologists insert a small catheter into an artery in the upper thigh or wrist. The catheter is then threaded into the arteries supplying the prostate. Small particles are injected to partially block the blood flow to the prostate. This reduces the size of the prostate and relieves symptoms of BPH.

Picel and team have treated almost 20 patients with the new procedure.

"We have seen excellent results with the patients we have treated so far," said Alexander Norbash, chair of Radiology at UC San Diego School of Medicine. "The benefits of PAE allow patients to recover at home and return more quickly to normal activities. Symptoms may start to improve as early as the first week after treatment."

Several surgery options are also available, including transurethral resection of the prostate (TURP), which is considered the gold standard for treatment of BPH. However, TURP requires full anesthesia, an overnight hospital stay, three to six weeks of recovery time and is associated with sexual side effects.

Enlarged prostates affect at least half of men over 60 years of age. Symptoms include a frequent urge to urinate, especially at night; leakage or dribbling of urine; a weak urine stream and trouble beginning urination. BPH can cause other problems if untreated, such as kidney, bladder and urinary tract infections.

UC San Diego Health interventional radiologists and urologists screen patients as potential candidates for PAE. Typically, candidates are 50 to 85 years of age, have urinary tract symptoms, have unsuccessfully tried medications within the last six months and have undergone assessment for prostate cancer risk. It is important that patients understand the full range of available treatment options to make an informed decision and pursue the treatment best for their individual medical situation.

"It is great that patients now have a minimally invasive alternative to surgery to help with this common health problem," said Picel. "The collaboration between interventional radiology and urology is why we are seeing such success treating patients with PAE."

###

In March of 2017, UC San Diego Health launched a clinical trial on PAE, making it one of the first medical centers in California to offer PAE. The clinical trial at UC San Diego Health is still ongoing and available to men who meet criteria clinicaltrials.ucbraid.org/trial/NCT03055624

For more information on PAE, visit health.ucsd.edu/specialties/radiology/ir/Pages/prostate-artery-embolization

Media Contact

Gabrielle Johnston, MPH
gnjohnston@ucsd.edu
858-249-0456
@UCSanDiego

http://www.ucsd.edu

Share12Tweet8Share2ShareShareShare2

Related Posts

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

October 30, 2026
Radiotherapy for oral cavity cancer: mucositis dominates while saliva and gum fluid stay largely stable

Radiotherapy for oral cavity cancer: mucositis dominates while saliva and gum fluid stay largely stable

October 30, 2026

Lung Cancer Pneumonia Risk Models Look Accurate but Almost All Are Flawed

October 30, 2026

Ear seeds ease chemotherapy nerve pain in trial, but only with in-person care

October 30, 2026
Please login to join discussion

POPULAR NEWS

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    29 shares
    Share 12 Tweet 7
  • Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

    29 shares
    Share 12 Tweet 7
  • ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

    29 shares
    Share 12 Tweet 7
  • Systematic review maps sustainability tensions in offshore wind development

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.